ECOG Performance StatusX X X ECOG score ( Appendix 7). Vital Signs X X XSee note in Table 2-1 . For BMS-9862 26, vital signs will be obtained before the infus ion and then every 15 minutes (±5 minutes) u ntil 4 hours after completion of the infusion on Cycle 1 Day 1. For cycle 2 Day 1 and ever y infusion thereafter, vital signs will be ob tained before the infusion and then every 15 m inutes ( ±5 minutes) for 60 minutes after th e completion of the infusion, For nivolumab or ipilimumab, vital signs will be obtained bef ore the infusion and then every 30 minutes ( ±10 minutes) until the start of BMS-986226 infusion or per institution guidelines for a dministration of nivolumab or ipilimumab. Th e 30-minute post nivolumab or ipilimumab infu sion vital signs may correspond to the pre-infusion BMS-986226 Revised Protocol No.: 04 Date: 31-May-2019 23 Approved 5.0 v Approved 1.0 v Clinical Protocol CA021002 BMS-986226 anti-ICOS Table 2-2: On-treatment Procedural Outline (CA021002) Procedures for Safety Cohort, and Parts A, B, C, D and Ea,bC1C2 to beyondC2 OnlyC2 OnlyNotes Procedure D1 D2D8 ±±1 daysD15 ±1 daysD22 ±1 daysD1 D2D8 ±1 daysEOT c,d,e vital signs. In th e event BMS-986226 administration i s delayed, nivolumab or ipilimumab vita l signs will be obtained until 60 minutes afte r completion of the infusion. If any vital sign is abnormal (based on clinician assess ment) at the final check, the participant mus t be observed further for a period of time, as clinically indicated. Revised Protocol No.: 04 Date: 31-May-2019 24 Approved 5.0 v Approved 1.0 v Clinical Protocol CA021002 BMS-986226 anti-ICOS Table 2-2: On-treatment Procedural Outline (CA021002) Procedures for Safety Cohort, and Parts A, B, C, D and Ea,bC1C2 to beyondC2 OnlyC2 OnlyNotes Procedure D1 D2D8 ±±1 daysD15 ±1 daysD22 ±1 daysD1 D2D8 ±1 daysEOT c,d,e Laboratory TestsSee Section 9.4.4 . On-study labor atory tests (including pregnancy testi ng) to be done on site/local within 72 hours prior to dosing on Day 1 of each cycle.